Spero Therapeutics(US:SPRO)2026-03-26 20:10Financial Performance - Spero reported a net income of $31.5 million for Q4 2025, compared to a net loss of $(20.9) million in Q4 2024, representing a significant turnaround [10]. - Total revenue for Q4 2025 was $41.3 million, up from $15.0 million in Q4 2024, primarily driven by increased collaboration revenue from agreements with GSK and Pfizer [10]. - Total revenue for the year ended December 31, 2025, was $66.8 million, compared to $48.0 million in 2024, reflecting a year-over-year increase of 39.2% [10]. - Spero received a $25 million milestone payment from GSK in Q1 2026 related to the NDA resubmission [10]. - Total liabilities decreased to $9.9 million as of December 31, 2025, from $64.4 million in 2024, indicating improved financial health [15]. Expenses - Research and development expenses decreased to $5.6 million in Q4 2025 from $28.8 million in Q4 2024, reflecting reduced clinical trial activity [10]. - General and administrative expenses for Q4 2025 were $4.3 million, down from $7.1 million in Q4 2024, due to lower legal and personnel-related costs [10]. Cash Position - As of December 31, 2025, Spero had cash and cash equivalents of $40.3 million, sufficient to fund operations into 2028 [10]. Regulatory and Clinical Updates - The NDA for tebipenem HBr was resubmitted to the FDA in December 2025, with a PDUFA date set for June 18, 2026 [5]. - The Phase 3 PIVOT-PO trial for tebipenem HBr demonstrated non-inferiority to intravenous imipenem-cilastatin, with results presented at IDWeek 2025 [5].